Numerous studies have established the association of MUC4 with the progression of cancer and metastasis. An aberrant expression of MUC4 is reported in precancerous lesions, indicating its early involvement in the disease process; however, its precise role in cellular transformation has not been explored. MUC4 contains many unique domains and is proposed to affect cell signaling pathways and behavior of the tumor cells. In the present study, to decipher the oncogenic potential of MUC4, we stably expressed the MUC4 mucin in NIH3T3 mouse fibroblast cells. Stable ectopic expression of MUC4 resulted in increased growth, colony formation, and motility of NIH3T3 cells in vitro and tumor formation in nude mice when cells were injected s.c. Microarray analysis showed increased expression of several growth-associated and mitochondrial energy production-associated genes in MUC4-expressing NIH3T3 cells. In addition, expression of MUC4 in NIH3T3 cells resulted in enhanced levels of oncoprotein ErbB2 and its phosphorylated form (pY 1248 -ErbB2). In conclusion, our studies provide the first evidence that MUC4 alone induces cellular transformation and indicates a novel role of MUC4 in cancer biology. [Cancer Res 2008;68(22):9231-8] 
Introduction
MUC4 is a member of the membrane-bound mucin family (1, 2) . It was cloned from a human tracheobronchial cDNA library and pancreatic tumor cell line and its complete genomic organization has been established (25 exons/introns over 65 kb; ref. 3) . MUC4 is synthesized as a single polypeptide chain of f930 kDa and hypothesized to be cleaved at a GDPH proteolytic cleavage site generating two subunits: the mucin type subunit MUC4a and a transmembrane subunit MUC4h. MUC4a possesses three putative functional domains: tandem repeat, nidogen-like, and adhesionassociated domain in MUC4 and other proteins, whereas MUC4h has three epidermal growth factor-like domains and a short cytoplasmic tail (3) .
MUC4 is normally expressed by the luminal epithelial cells of the stomach, colon, lung, trachea, cervix, and prostate (4, 5) , although it is not or minimally expressed by gall bladder, biliary epithelial cells, intrahepatic bile ducts, liver, and pancreas (4, 6, 7) . An overexpression of MUC4 is, however, observed in pancreatic, lung, breast, colon, and ovarian malignancies, suggesting its pathologic significance (6, (8) (9) (10) . Furthermore, the association of MUC4 with the poor prognosis of the pancreatic, lung, and bile duct cancer patients has also been reported (11) (12) (13) . Using MUC4 knockdown and overexpression cell models, we have shown that MUC4 potentiates pancreatic tumor cell growth and metastasis by altering the behavioral properties of the tumor cells (14) (15) (16) . Importantly, our recent studies have revealed that MUC4 interacts with the receptor tyrosine kinase HER2 and regulates its expression by posttranslational mechanisms (17) . HER2 is an established oncoprotein and is involved in growth and malignant properties of the cancer cells (18) . An aberrant expression of MUC4 in pancreatic cancer is detected early (i.e., in precancerous lesions) and correlates with the disease advancement (19, 20) . All these findings indicate that MUC4 may play an important role in the early and late events of cancer progression.
In the present study, we have carried out a set of experiments to define the role of MUC4 in oncogenic transformation. MUC4 was ectopically overexpressed in NIH3T3 mouse fibroblast cells by stable transfection and its effect on the cellular phenotype was determined by performing in vitro and in vivo functional assays. Ectopic expression of MUC4 in NIH3T3 cells resulted in increased growth, colony formation, and motility of the cells. Furthermore, MUC4-expressing NIH3T3 cells spontaneously formed tumors in nude mice in majority of cases (73%) when injected s.c. An enhanced expression of ErbB2, its phosphorylated form (pY 1248 -ErbB2), and phosphorylated extracellular signal-regulated kinase (pERK) was observed in MUC4-expressing NIH3T3 cells. Additionally, ectopic expression of MUC4 was found to alter the expression of several growth-associated and mitochondrial energy production-associated genes. Together, all these observations support a role of MUC4 in cancer pathogenesis and provide first evidence for its oncogenic action.
Materials and Methods
Cell culture and transfection. NIH3T3 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 Ag/ mL penicillin and 100 Ag/mL streptomycin). Cells were grown at 37jC with 5% CO 2 in a humidified atmosphere. pSecTagC-MUC4 plasmid, previously designed in our lab (16) , was used for attaining the ectopic expression of MUC4 in NIH3T3 mouse fibroblast cells by stable transfection using FuGENE6 Transfection Reagent (Roche Diagnostics). Cells were also transfected with empty pSecTagC vector to obtain a control population. The zeocin-resistant colonies were isolated by the ring cloning method, expanded, and maintained in medium supplemented with 400 Ag/mL zeocin (Invitrogen).
Immunoblot assay. The NIH3T3-derived clones were processed for protein extraction and Western blotting using standard procedures. Cell lysates were prepared as described previously (15) . Protein concentrations were determined using a Bio-Rad detergent-compatible protein estimation kit. For MUC4, the proteins (20 Ag) were resolved by electrophoresis on a 2% SDS-agarose gel under reducing conditions. For h-actin, ErbB2, pY 1248 -ErbB2, and ERK1/2, SDS-PAGE (10%) was performed under similar conditions. Resolved proteins were transferred onto the polyvinylidene difluoride (PVDF) membrane and blocked in 5% nonfat milk in PBS for 2 h and subjected to the standard immunodetection procedure using specific antibodies. For h-actin immunodetection, anti-h-actin mouse monoclonal antibody (mAb; Sigma) in dilution of 1:2,000 (used as internal control) was used; for MUC4 immunodetection, anti-MUC4 mouse mAb (8G7, generated in our laboratory) in dilution of 1:1,000 was used. For ErbB2, pY 1248 -ErbB2, ERK, and pERK immunodetection, anti-ErbB2 (Santa Cruz Biotechnology), anti-pY 1248 -ErbB2 (Upstate), anti-ERK1/2 (Santa Cruz Biotechnology), and anti-pERK1/2 (Cell Signaling Technology) rabbit polyclonal antibodies in dilution of 1:1,000 were used. The membranes were incubated for 4 h at room temperature followed by six 10-min washes in TBST [50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, and 0.05% Tween 20] . Further, the membranes were incubated in horseradish peroxidase (HRP)-conjugated secondary antibodies (diluted at 1:2,000 in PBS; Amersham Biosciences) for 1 h at room temperature followed by six washes in TBST. The blots were processed with enhanced chemiluminescence kit (Amersham Biosciences), and the signal was detected by exposing the processed blots to X-ray films (Biomax Films).
Confocal immunofluorescence microscopy. For immunofluorescence staining, cells were grown at low density on sterilized coverslips for 20 h. Cells were first washed with 0.1 mol/L HEPES containing Hanks' buffer and then fixed in ice-cold methanol at À20jC for 2 min. Methanol-fixed cells were blocked in 10% goat serum containing 0.05% Tween 20 for 30 min at room temperature for nonspecific blocking followed by incubation with the anti-MUC4 mAb (8G7), diluted (1:100) in PBS, for 90 min at room temperature. Cells were washed four to five times for 5 min with PBS containing 0.05% Tween 20 (PBS-T) and then incubated with FITCconjugated goat anti-mouse secondary antibodies (Jackson ImmunoResearch Laboratories, Inc.) for 60 min. Cells were again washed four to five times for 5 min with PBS-T and mounted on glass slides in antifade Vectashield mounting medium (Vector Laboratories). Immunostaining was observed under a Zeiss confocal laser-scanning microscope, and representative photographs were captured digitally using 510 LSM software.
Growth kinetics assay. Cells (2.5 Â 10 4 ) in 2 mL of DMEM containing 1.0% FBS were seeded in six-well plates and allowed to grow for different time intervals. The growth of the cells was monitored by counting the number of cells using a hemocytometer everyday for 10 d. The cell population doubling time (T d ) was calculated during the exponential growth phase (192-240 h) using the following formula: T d = 0.693t/ln (N t /N 0 ) (15) , where t is time difference (in h), N t is the cell number at time t (240 h), and N 0 is the cell number at initial time (192 h).
Colony-forming assay. Cells were seeded in triplicate at a density of 2.5 Â 10 3 per 10-cm dishes in DMEM containing 1.0% FBS. After 2 wk of growth, the cells were fixed and stained with crystal violet stain (0.1%, w/v) in 20 nmol/L MOPS (Sigma Chemical). Cells in 10 random fields of view at Â100 magnification were counted and expressed as the average number of cells per field of view.
In vivo tumorigenicity assay. To test the tumorigenicity, the MUC4-transfected NIH3T3 cells along with the control cells were harvested from subconfluent cultures by a brief exposure to 0.25% trypsin and 0.02% EDTA. Trypsinization was stopped with medium containing 10% FBS, and the cells were washed once in PBS. Cell viability and count were determined by trypan blue staining using a hemocytometer. Cells were resuspended in a normal saline solution at a concentration of 10 Â 10 6 /mL. Single-cell suspensions of >90% viability were used for the injections. Immunodeficient mice were purchased from the Animal Production Area of the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD). The mice were housed in pathogen-free conditions, fed sterile water and food ad libitum, and treated in accordance with the Institutional Animal Care and Use Committee guidelines. Viable MUC4-transfected or empty vector-transfected NIH3T3 cells (1 Â 10 6 ), suspended in a normal saline solution, were injected s.c. in immunodeficient mice (n = 15). To quantify tumor growth, two perpendicular tumor dimensions (a and b) were measured twice a week with a Vernier caliper, and tumor surface area (mm 3 ) was calculated by the following formula for each time period: (21) . Tumor volumes were compared between mice injected with NIH3T3/MUC4 and NIH3T3/pSecTag cells. Differences in tumor-free survival were displayed using Kaplan-Meier plots and survival curves were compared using the log-rank test. All mice were sacrificed on day 36 after transplantation, and the presence of metastatic lesions in different organs was also determined.
Motility assay. For motility assays, 1 Â 10 6 cells were plated in the top chamber of noncoated polyethylene terephthalate membranes (six-well insert, 8-mm pore size; Becton Dickinson). The cells were incubated for 24 h, and the cells that did not migrate through the pores in the membrane were removed by scraping the membrane with a cotton swab. Cells that traversed through the membrane pores were stained with a Diff-Quick cell staining kit (Dade Behring, Inc.). Cells in 10 random fields of view at Â100 magnification were counted and expressed as the average number of cells per field of view. Two independent experiments were done in each case. The Figure 1 . Western blot and confocal immunofluorescence analyses of MUC4 expression in empty vector-transfected and MUC4-transfected NIH3T3 cells. A, a total of 20 Ag protein from cell extracts were resolved by electrophoresis on a 2% SDS-agarose gel, transferred to PVDF membrane, and incubated with anti-MUC4 mAb (8G7). The membrane was then probed with HRP-labeled goat anti-mouse immunoglobulin. Immunoblot of h-actin, obtained from 10% SDS-PAGE, was used as an internal control. The signal was detected using an electrochemiluminescence reagent kit. B, cells were grown at low density on sterilized coverslips and processed for the immunofluorescence procedure after fixation in methanol for 10 min. Slides were incubated with MUC4 mAb (8G7) followed by FITC-conjugated secondary antibody and were observed under a Zeiss confocal laser-scanning microscope.
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Oligonucleotide array gene expression analysis. Mouse oligonucleotide array containing probes for f10,800 genes was constructed at the Microarray Core Facility of University of Nebraska Medical Center. Total RNA was isolated from MUC4 and empty vector-transfected NIH3T3 cells by RNeasy Mini kit (Qiagen). Spotted microarrays were used to determine differential gene expression between NIH3T3/MUC4 and NIH3T3/pSecTag samples. The design had NIH3T3/MUC4 and NIH3T3/pSecTag samples competitively hybridized to three arrays. To generate the fluorescently labeled, single-stranded cDNA target, total RNA (750 ng) was reverse transcribed to generate cDNA, followed by in vitro transcription to generate amino-allyl (aRNA) using the Amino Allyl Message Amp kit (Ambion). aRNA (5 Ag) was coupled with either CY5 or CY3 dye as per the manufacturer's suggestion, mixed, and cohybridized (in 20 AL of Ambion hybridization buffer) to microarray slides for 16 h at 42jC. The slides were washed per the manufacturer's suggestions and scanned using an Axon 4000b scanner to generate .tiff images. The images were extracted using GenePix software and resultant .GPR files were used for downstream analysis. Differentially expressed genes were identified using BRB Array Tools developed by Dr. Richard Simon and Amy Peng (Biometric Research Branch, National Cancer Institute, NIH, Bethesda, MD).
Several filters and normalization were applied before analysis. Spots were excluded if both the red and green channels had values <100, and if only one of the red or green channels was <100, it was increased to the threshold of 100. Median background was subtracted and log 2 transformation was applied to all ratios. Normalization was then done to ''center'' each array using lowess smoother and genes were excluded if any of the spots were missing or filtered out for any of the samples. Random-variance paired t tests were used to determine which genes are differentially expressed between NIH3T3/MUC4 and NIH3T3/pSecTag samples, comparing the log red (NIH3T3/MUC4) and green (NIH3T3/pSecTag) channel intensities. The random-variance paired t test allows sharing information among genes about variation without assuming that all genes have the same variance, which gives a more accurate estimate of the variability when sample sizes are small. A significance level of 0.001 was selected to help limit the false discovery rate due to multiple comparisons.
Quantitative reverse transcription-PCR. Total RNA (2 Ag) from each of the derived NIH3T3 cell lines was reverse transcribed using the first-strand cDNA synthesis kit (Perkin-Elmer) and oligo-d(T) primers according to the manufacturer's instructions. Real-time PCR amplifications were carried out with 100 ng of first-strand cDNA in 10-AL reaction volumes. The reaction mixture was subjected to a two-step cyclic program (95jC for 10 min followed by 40 cycles of 95jC for 15 s and 60jC for 1 min) as per the manufacturer's protocol on ABI 7500 sequence detection system (Applied Biosystems) with SYBR chemistry. Predesigned PCR primers for Tln, Sna, Nek6, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were purchased from a commercial source (SuperArray Biosciences Corp.). The , where t is time (in h), N t is the cell number at time t , and N 0 is the cell number at initial time. Columns, mean (n = 3); bars, SE. *, P < 0.05. C, colony formation assay was performed by seeding 2,500 cells in 10-cm dishes and grown for 2 wk. Cells were fixed and stained with 0.1% crystal violet and representative photographs were taken for NIH3T3/MUC4 and NIH3T3/pSecTag cells. The NIH3T3/MUC4 cells showed significant increase in colony formation compared with control NIH3T3/pSecTag cells. Columns, mean (n = 20); bars, SE. *, P < 0.003. D, motility assay was performed by plating the cells onto noncoated membranes and subsequent incubation for 24 h. Medium containing 10% FBS in the lower chamber was used as a chemoattractant. Cells that migrated through the pores were fixed and stained, and representative fields were photographed under bright-field microscopy with Â100 magnification. The number of cells transversing the membrane was determined by averaging 10 random fields of view at Â100 and expressed as the average number of cells per field of view and is the average of two independent experiments. The NIH3T3/MUC4 cells showed significant increase (f2-fold) in cell motility compared with control NIH3T3/pSecTag cells. Columns, mean (n = 20); bars, SE. *, P < 0.04 Â 10 À7 . 
MUC4 Induces Oncogenic Transformation

Results
Constitutive overexpression of MUC4 in mouse fibroblast NIH3T3 cells. To investigate the transforming ability of MUC4, mouse fibroblast NIH3T3 cells that do not express endogenous Muc4 were transfected with human MUC4 expression plasmid (pSecTag-MUC4; ref. 16) or empty pSecTag vector (as a control) and stable cell clones were selected. The clones were expanded and screened for MUC4 expression by immunoblot analysis. Two clones that exhibited high level of MUC4 (Fig. 1A) were pooled together and further characterized by confocal analysis (Fig. 1B) . The pooled populations of MUC4-transfected (NIH3T3/MUC4) and empty vector-transfected (NIH3T3/pSecTag) cells were monitored for 1 to 2 months for stable expression and used to study the oncogenic potential of MUC4 and its effect on cellular phenotype by performing in vitro and in vivo functional assays.
Ectopic expression of human MUC4 enhances the growth kinetics and clonogenicity of NIH3T3 cells. To determine whether MUC4 influences the growth of NIH3T3 cells, NIH3T3/ MUC4 and NIH3T3/pSecTag cells were seeded at low density (25 Â 10 3 per well of six-well plate) and growth rates were determined by cell counting at different time intervals (Fig. 2A) . NIH3T3/MUC4 cells showed an enhanced growth rate compared with the empty vector-transfected (NIH3T3/pSecTag) cells. Population doubling times were calculated from the growth curve during the exponential phase (192-240 hours). NIH3T3/MUC4 cells displayed a significant decrease (P < 0.05) in doubling time compared with the control cells. NIH3T3/MUC4 cells had a doubling time of 37 hours, whereas it was recorded 44 hours for the control cells (Fig. 2B) . To assess the effects of MUC4 expression on the plating efficiency of NIH3T3 cells, NIH3T3/MUC4 and NIH3T3/pSecTag cells were analyzed by colony formation assay. Cells were seeded at very low density (2.5 Â 10 3 per 10-cm dish), and after 2 weeks, cells were fixed and stained with 0.1% crystal violet and representative photographs were taken. NIH3T3/MUC4 cells showed significantly enhanced colony formation when compared with the vector-transfected cells (Fig. 2C) .
MUC4 expression enhances motility of NIH3T3 cells. To examine the effect of MUC4 expression on NIH3T3 cells on behavioral properties, a motility assay was performed by using uncoated porous membranes of 8.0-mm pore diameter. The number of cells that migrated to the lower surface of the porous membrane under chemoattractive stimulus of FBS in the lower chamber was f2-fold greater in MUC4-expressing NIH3T3/MUC4 cells in comparison with control NIH3T3/pSecTag cells (Fig. 2D) . These data indicated that expression of MUC4 enhanced motility in NIH3T3 cells.
Expression of MUC4 induces oncogenic transformation of NIH3T3 cells. To test the hypothesis that MUC4 plays a role in cellular transformation and potentiation of tumor development, we examined the tumorigenic potential of NIH3T3/MUC4 and NIH3T3/pSecTag cells in vivo. A total of 30 immunodeficient mice were injected s.c. with NIH3T3/MUC4 and NIH3T3/pSecTag cells (1 Â 10 6 ) and tumor growth was measured twice a week in two independent experiments. Tumor volumes were calculated from bidimensional measurements at each time point and mice were sacrificed on day 36 after injection. Results were expressed as differences in tumor-free survival and tumor volumes were also compared between these two groups. The tumor-free survival experience was significantly decreased in NIH3T3/MUC4 cellinjected mice (P < 0.001). The mean tumor-free survival time for NIH3T3/MUC4 mice (n = 15) was only 17.6 days compared with 34.7 days for control animals (n = 15; Fig. 3A ). Only 7% of mice injected with MUC4-expressing NIH3T3 cells showed tumor-free survival on 36th day of implantation of cells compared with 73% Figure 3 . MUC4 induces tumorigenicity in NIH3T3 cells. NIH3T3/MUC4 and NIH3T3/pSecTag cells (1 Â 10 6 ) were injected s.c. into the nude mice. Tumor volumes were calculated from bidimensional measurements at each time point. Results were expressed as differences in tumor-free survival and tumor volumes between mice injected with NIH3T3/MUC4 and NIH3T3/pSecTag cells; each group includes 15 mice per group. A, differences in tumor-free survival were measured using Kaplan-Meier plots and survival curves were compared using the log-rank test. B, tumor volumes were compared between these groups. Points, mean; bars, SE. of mice injected with control cells. Furthermore, tumor volumes were significantly increased in mice injected with NIH3T3/MUC4 cells compared with the mice injected with empty vectortransfected NIH3T3/pSecTag cells (P < 0.05; Fig. 3B ). No observable metastasis, however, was observed in any of the control-injected or NIH3T3/MUC4 cell-injected mice.
MUC4 expression enhances the expression of ErbB2 and its downstream signaling in NIH3T3 cells. In our previous studies, a reduced level of total and phosphorylated (at Tyr 1248 ) HER2 protein was found in MUC4 down-regulated CD18/HPAF cells (14, 15) . Furthermore, we have recently provided evidence that MUC4 interacts with HER2 and regulates its expression (17) . In other studies, the rat homologue of MUC4 (rMuc4) has also been shown to interact with ErbB2/HER2/neu and induce its limited phosphorylation (23) . Based on these observations, we wanted to determine whether MUC4 regulates the expression of ErbB2 protein and thus of pY 1248 -ErbB2 in NIH3T3 cells. Our results clearly show that NIH3T3/MUC4 cells have increased levels of total ErbB2 and pY 1248 -ErbB2 protein compared with the control NIH3T3/pSecTag cells (Fig. 4) . MUC4-associated increased expression and activity of HER2 is associated with enhanced phosphorylation of ERK (17) . Consistent with our previous observations, NIH3T3/MUC4 cells also showed an increased phosphorylation of ERKs [p42/44 mitogen-activated protein kinase (MAPK)] compared with the control NIH3T3/pSecTag cells.
MUC4-associated alterations of gene expression in NIH3T3 cells. DNA oligonucleotide microarrays representing f10,800 genes were used to identify genes regulated by MUC4 and potentially responsible for tumorigenic potential of MUC4-expressing NIH3T3/MUC4 cells and its effect on the cellular phenotype. The mRNA expression profile of NIH3T3/MUC4 cells was compared with that of NIH3T3/pSecTag cells. Among all the genes, 59 showed at least 1.8-fold change in expression after normalization. Out of these genes, a few selected genes that were either overexpressed or down-regulated in the MUC4-expressing cells are listed in Table 1 . Analysis of the data revealed that several growth-associated and energy production-associated genes were up-regulated in the MUC4-expressing cells. Additionally, several genes associated for cell motility were also altered. Genes of particular importance, which were differentially expressed in MUC4-expressing NIH3T3 cells, were those encoding for Nek6, Sna, Gas5, S100A11, Cox3, ND1, Pkp3, HM13, trim16, atf7ip, and Talin. To validate our microarray data, expression of few randomly selected differentially expressed genes was examined by quantitative reverse transcription-PCR (RT-PCR; Supplementary Fig. S1 ). The results of RT-PCR were in complete agreement with the microarray data, indicating that these alterations in gene expression could be functionally implicated in MUC4-mediated cellular transformation and phenotypic changes of NIH3T3 cells.
Discussion
Mucins are high molecular weight glycoproteins secreted by epithelial cells for the lubrication and protection of vulnerable surfaces. Mucins are also believed to play an important role in the pathogenesis of benign and malignant diseases of secretory epithelial cells (24) . Our previous studies have shown the specific and differential expression of MUC4 in pancreatic adenocarcinomas compared with the normal pancreas or chronic pancreatitis (6) . Furthermore, we have observed 100% incidence of MUC4 overexpression in early stage of ovarian cancer, whereas only a faint staining was observed in some cases of nonneoplastic ovary (25) . An up-regulation of MUC4 has also been observed in variety of other human adenocarcinomas, such as squamous cell carcinoma, lung carcinoma, and mammary and colon cancer (9, 10, 26) . De novo expression of MUC4 in precancerous pancreatic intraepithelial neoplasias and a progressive increase in its expression with disease advancement implicate MUC4 as an important player in the early and late phases of pancreatic cancer development (20) . In fact, our earlier studies have clearly shown the pathogenic functions of MUC4 in pancreatic cancer progression (14, 15) . Here, we have presented data showing the oncogenic potential of MUC4 and thus its role in early stages of cancer development. The findings from the present study showed that the ectopic expression of MUC4 increased in vitro growth and colony formation in NIH3T3 cells and induced spontaneous tumor formation in vivo. MUC4 expression was also associated with increased motility of cells. Moreover, ectopic expression of MUC4 was found to alter the expression of several growth-associated and energy productionassociated genes.
Cellular transformation involves the increased expression or activity-promoting mutation(s) in growth-enhancing genes and/or deletion/mutational inactivation of the growth suppressor genes (27) . Mucins, MUC4 and MUC1 (another transmembrane mucin), are now well recognized for their growth-promoting activity Research.
on January 28, 2018. © 2008 American Association for Cancer cancerres.aacrjournals.org Downloaded from (24, 28) . In fact, MUC1 was also shown to induce oncogenic transformation (29) . The role of MUC4 in cellular transformation, however, was not defined thus far, and therefore, the present study provides first evidence on the role of MUC4 in early phase of oncogenesis. Another important observation in the present study was an enhanced expression of ErbB2 and pY 1248 -ErbB2 in MUC4-expressing NIH3T3 cells compared with the control cells. This was consistent with our previous reports in pancreatic cancer cells (15, 17) . ErbB2 is a receptor tyrosine kinase, and its overexpression has been shown to correlate with aggressiveness, prognosis, and invasive behavior of various tumors (30) . In other studies, SMC/ Muc4 (the rat homologue of MUC4) was also shown to act as an intramembrane ligand for ErbB2/HER2/neu, inducing its limited phosphorylation (31) . Quantitation of ErbB2 transcripts did not show an overexpression (data not shown), which substantiates our recent finding that MUC4 affects ErbB2 expression posttranslationally and increases the stability of ErbB2 protein (17) . Interestingly, NIH3T3/MUC4 cells showed an increased phosphorylation of ERKs (p42/44 MAPK) compared with control NIH3T3/ pSecTag cells. The HER2-mediated activation of the ERK pathway plays a crucial role in mediating transformation and cell proliferation. It will be of interest to examine the correlation between the expression of MUC4, HER2, and other downstream mediators and their activation status in clinical samples to support the pathogenic relevance.
An altered expression of genes is observed in response to ectopic expression of MUC4 in NIH3T3 cells (Table 1 ). MUC4 expression in NIH3T3 cells up-regulated the expression of Cox3 and ND1 proteins associated with mitochondrial ATP production. Various genes coding for mitochondrial proteins have also been previously identified as being up-regulated in MUC4-expressing pancreatic cancer cells (16) . It has been postulated that MUC4-mediated increase in mitochondrial proteins is associated with an increase in metabolic activity and thereby decrease in cancer cell death (16) . Although NIH3T3/MUC4 cells showed increased in vitro growth compared with control cells, we did not find any significant difference in cell death. An up-regulation of Sna and downregulation of Talin and Pkp3, which are implicated in cell motility, were also observed. Sna is a transcription factor that induces epithelial-mesenchymal transitions responsible for acquisition of motile and invasive properties during tumor progression (32, 33) . Pkp3 is a protein of desmosomal plaque and all histologic grades of squamous cell carcinoma tissues were shown to be negative for Pkp3 expression (34) . Talin is an actin-binding cytoskeletal protein that plays an essential role in the formation of integrin cell adhesion proteins. A recent study showed complete deexpression of Talin in endometrioid carcinoma tissues (35) . An upregulation of the Nek6, S100A11, Gas5, IL18R1, and trim16 was also reported in MUC4-overexpressing NIH3T3 cells compared with control cells. All these proteins are key regulators of cell growth. Nek6 is a protein kinase, critical for cell cycle progression (36) , and calcium-binding protein S100A11 is correlated with the growth of human uterine leiomyoma (37) . Gas5 is regarded as a useful marker for growth arrest, proliferation, and differentiation in the developing embryo (38) . It has been identified as significantly up-regulated in benzo(a)pyrene-treated smooth muscle cells as an apoptosis inhibitor for survival of cells by cDNA microarray analysis (39) . Trim and IL18R proteins are involved in a variety of biological processes, including cell growth and cancer pathogenesis (40, 41) . Hence, these altered genes might be responsible for MUC4-mediated induction of cell transformation.
In conclusion, our data provide first evidence on the role of MUC4 mucin in cellular transformation. We show that MUC4 induces tumor formation in vivo and results in an enhanced cell growth, colony formation, motility, and a change in expression of various growth-associated and mitochondrial energy productionassociated genes. Furthermore, we also show that expression of MUC4 is associated with enhanced levels of oncoprotein ErbB2 and pY 1248 -ErbB2. An increased phosphorylation of ERK1/2, downstream targets of ErbB2, was also observed. The events downstream of MUC4 that promote tumorigenesis are still unclear but could conclude enhancing conditions for cell proliferation. A model (Fig. 5) has been proposed to depict the possible mechanism of MUC4 in oncogenic transformation. Hence, MUC4 mucin presents an attractive target for cancer prevention and therapeutics with the potential of inhibiting the initiation and growth of human cancer cells. 
